Specific microchlasmic antigen receptors with CD19 containing the CD28 / CD40 excitemental region

VN8349UPending Publication Date: 2026-11-02MAHIDOL UNIV +1
0 Cites 0 Cited by

Patent Information

Application Number
VN2202600912
Authority / Receiving Office
VN · VN
Patent Type
Utility models
Current Assignee / Owner
Filing Date
2025-02-05
Publication Date
2026-11-02
Estimated Expiration
2035-02-05
Patent Text Reader

Abstract

The proposed solution refers to a genetically modified CD19-specific mosaic antigen receptor containing the CD28 / CD40 co-stimulatory domain (CAR-CD19z.CD28.CD40), specifically at the signaling domains of the CD28 / CD40 co-stimulatory domain, which is transduced into T cells to generate genetically modified T cells expressing CAR-CD19z.CD28.CD40 on their surface. These T cells are used to treat cancers that express the CD19 antigen on their cell surfaces, such as leukemia and lymphoma. Additionally, they can effectively reduce relapse or drug resistance.
Need to check novelty before this filing date? Find Prior Art